MCID: LPC002
MIFTS: 52

Lip Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Eye diseases, Genetic diseases

Aliases & Classifications for Lip Cancer

MalaCards integrated aliases for Lip Cancer:

Name: Lip Cancer 12 14
Lip Neoplasms 42 69
Malignant Neoplasm of Oral Aspect of Lip, Not Specified Whether Upper or Lower 12
Malignant Neoplasm of External Lip, Not Specified As Upper or Lower 12
Malignant Neoplasm of Vermilion Border of Lip Unspecified 12
Malignant Neoplasm of Lip, Unspecified, Vermilion Border 12
Malignant Neoplasm of Lip, Unspecified, Inner Aspect 12
Malignant Neoplasm of Lip Unspecified, Inner Aspect 12
Malignant Neoplasm of Lower Lip, Inner Aspect Nos 12
Malignant Neoplasm of Lip, Unspecified, External 12
Malignant Neoplasm of Lip, Vermilion Border Nos 12
Malignant Neoplasm of Labial Commissure of Lip 12
Malignant Neoplasm of Lower Lip, Buccal Aspect 12
Malignant Neoplasm of Vermilion Border of Lip 12
Malignant Neoplasm of Lower Lip, Oral Aspect 12
Malignant Neoplasm of Lip, Inner Aspect Nos 12
Malignant Neoplasm of Other Sites of Lip 12
Malignant Neoplasm of Commissure of Lip 12
Malignant Neoplasm of Lip, Inner Aspect 12
Malignant Neoplasm of Lower Lip, Mucosa 12
Malignant Neoplasm of Lip, Unspecified 12
Malignant Tumor of Lower Labial Mucosa 12
Malignant Tumour of Labial Commissure 12
Malignant Tumor of Commissure of Lip 12
Malignant Tumor of Labial Mucosa 12
Malignant Tumor of the Lip 12
Malignant Tumour of Lip 12
Malignant Tumor of Lip 12
Cancer of Lip 69

Classifications:



Summaries for Lip Cancer

MalaCards based summary : Lip Cancer, also known as lip neoplasms, is related to lower lip cancer and upper lip cancer. An important gene associated with Lip Cancer is SUMO1 (Small Ubiquitin-Like Modifier 1), and among its related pathways/superpathways are Gene Expression and Cytokine Signaling in Immune system. The drugs Cisplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and liver, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and cellular

Related Diseases for Lip Cancer

Diseases in the Lip Cancer family:

Pre-Malignant Neoplasm Lip Carcinoma in Situ
in Situ Carcinoma Eye Carcinoma in Situ
Familial/multiple Cancer

Diseases related to Lip Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
id Related Disease Score Top Affiliating Genes
1 lower lip cancer 12.0
2 upper lip cancer 11.9
3 oral cancer 10.6
4 mirror polydactyly-vertebral segmentation-limbs defects syndrome 10.4 BRAF TP53
5 pilocytic astrocytoma of cerebellum 10.4 BRAF TP53
6 split hand split foot nystagmus 10.4 BRAF TP53
7 coloboma of inferior eyelid 10.4 BRAF TP53
8 malignant syringoma 10.4 BRAF TP53
9 gliofibroma 10.3 BRAF TP53
10 vulvar keratoacanthoma-like carcinoma 10.3 MSH2 TP53
11 rnase t2-deficient leukoencephalopathy 10.3 MDM2 TP53
12 maxillary neoplasm 10.3 MSH2 TP53
13 rectum squamous cell carcinoma 10.3 MDM2 TP53
14 vulvar liposarcoma 10.3 MDM2 TP53
15 sternum cancer 10.3 BRAF TP53
16 breast epithelioid hemangioma 10.3 MDM2 TP53
17 cellular myxoid liposarcoma 10.3 MSH2 TP53
18 endodermal sinus tumor 10.3 MDM2 TP53
19 secondary pulmonary hemosiderosis 10.3 MDM2 TP53
20 ascaridiasis 10.2 MDM2 TP53
21 lymphopenia 10.2 MDM2 TP53
22 sparse hair ptosis mental retardation 10.2 MDM2 TP53
23 bladder squamous cell carcinoma 10.2 MDM2 TP53
24 biliary dyskinesia 10.2 MDM2 TP53
25 enamel hypoplasia cataract hydrocephaly 10.2 MDM2 TP53
26 c-p angle neurinoma 10.2 MDM2 TP53
27 childhood medulloblastoma 10.2 MDM2 TP53
28 hereditary nephrotic syndromes, autosomal dominant 10.2 BRAF MSH2
29 mediastinum rhabdomyosarcoma 10.2 MDM2 TP53
30 congenital hypomyelination neuropathy 10.2 MSH2 TP53
31 cystic lymphangioma 10.2 MDM2 TP53
32 gestational choriocarcinoma 10.1 MDM2 TP53
33 vitamin d-dependent rickets, type i 10.1 MDM2 TP53
34 rete testis adenoma 10.1 CDKN1A TP53
35 spindle cell sarcoma 10.1 MDM2 TP53
36 ureter urothelial papilloma 10.1 CDKN1A TP53
37 trachea squamous cell carcinoma 10.1 MSH2 TP53
38 congenital granular cell tumor 10.1 CDKN1A TP53
39 superior vena cava angiosarcoma 10.0 MDM2 TP53
40 mixed extragonadal germ cell cancer 10.0 MDM2 TP53
41 dubin-johnson syndrome 10.0 BRAF TP53
42 tenosynovitis of foot and ankle 10.0 CDKN1A TP53
43 adenosarcoma 9.9 MDM2 TP53
44 lymphoplasmacytic lymphoma 9.9 MSH2 TP53
45 fallopian tube mucinous tumor 9.9 CDKN1A TP53
46 hodgkin's lymphoma, mixed cellularity 9.9 CDKN1A TP53
47 familial episodic pain syndrome 9.9 BRAF MSH2 TP53
48 arteritic anterior ischemic optic neuropathy 9.9 BRAF MSH2 TP53
49 childhood optic nerve glioma 9.9 BRAF MSH2 TP53
50 fallopian tube adenomatoid tumor 9.8 CDKN1A MDM2

Graphical network of the top 20 diseases related to Lip Cancer:



Diseases related to Lip Cancer

Symptoms & Phenotypes for Lip Cancer

GenomeRNAi Phenotypes related to Lip Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.1 BRAF CDKN1A MDM2 MSH2 SUMO1 TP53

MGI Mouse Phenotypes related to Lip Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.91 MDM2 MSH2 SUMO1 TP53 BRAF CDKN1A
2 digestive/alimentary MP:0005381 9.85 BRAF CDKN1A MDM2 MSH2 SUMO1 TP53
3 craniofacial MP:0005382 9.8 BRAF CDKN1A MDM2 SUMO1 TP53
4 integument MP:0010771 9.72 BRAF CDKN1A MDM2 MSH2 TP53
5 mortality/aging MP:0010768 9.63 BRAF CDKN1A MDM2 MSH2 SUMO1 TP53
6 liver/biliary system MP:0005370 9.56 BRAF CDKN1A MDM2 TP53
7 neoplasm MP:0002006 9.35 BRAF CDKN1A MDM2 MSH2 TP53
8 renal/urinary system MP:0005367 8.92 BRAF CDKN1A MDM2 TP53

Drugs & Therapeutics for Lip Cancer

Drugs for Lip Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 297)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
4
Aldesleukin Approved Phase 3,Phase 2 85898-30-2, 110942-02-4
5
Tegafur Approved Phase 3,Phase 2 17902-23-7 5386
6
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
7
Epirubicin Approved Phase 3,Phase 1,Phase 2 56420-45-2 41867
8 Racepinephrine Approved Phase 3
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
11
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
12
Pilocarpine Approved Phase 3,Phase 2 54-71-7, 92-13-7 5910
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Bleomycin Approved Phase 3 11056-06-7 5360373
15
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
16
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
17
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
18
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
19
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
20
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
21
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
22
Doxepin Approved Phase 3 1668-19-5 667477 667468
23
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
24
Isotretinoin Approved Phase 3,Phase 2 4759-48-2 5538 5282379
25
Bevacizumab Approved, Investigational Phase 3,Phase 1,Phase 2 216974-75-3
26
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
28
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
29 Tocopherol Approved, Nutraceutical Phase 3
30
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
31
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
32 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
33 Antimetabolites Phase 3,Phase 1,Phase 2
34 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
35
Cobalt Phase 3 7440-48-4 104729
36 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
37 calcium heparin Phase 3
38 Coagulants Phase 3
39 Hemostatics Phase 3
40 Tolonium Chloride Phase 3
41 Pharmaceutical Solutions Phase 3,Phase 1,Early Phase 1
42 Anti-HIV Agents Phase 3,Phase 2
43 Anti-Infective Agents Phase 3,Phase 2,Phase 1
44 Anti-Retroviral Agents Phase 3,Phase 2,Phase 1
45 Antiviral Agents Phase 3,Phase 1,Phase 2
46 Interleukin-2 Phase 3,Phase 2
47
s 1 (combination) Phase 3,Phase 2
48 Adrenergic Agents Phase 3,Phase 2
49 Adrenergic Agonists Phase 3
50 Adrenergic alpha-Agonists Phase 3

Interventional clinical trials:

(show top 50) (show all 376)

id Name Status NCT ID Phase Drugs
1 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
2 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
3 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
4 Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Unknown status NCT00655421 Phase 3
5 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
6 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
7 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
8 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
9 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
10 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
11 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
12 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
13 Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00003139 Phase 3 pilocarpine hydrochloride
14 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
15 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
16 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
17 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
18 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3 cisplatin;fluorouracil;paclitaxel
19 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3 cisplatin;fluorouracil
22 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
23 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
24 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
25 Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Completed NCT00004917 Phase 3 cisplatin
26 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed NCT00095875 Phase 3 carboplatin;cisplatin;docetaxel;fluorouracil
27 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
28 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
29 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
30 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
31 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
32 Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002654 Phase 3 chemotherapy;cisplatin
33 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
34 Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00003328 Phase 3 porfiromycin
35 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
36 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
37 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
38 High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002555 Phase 3 cisplatin
39 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
40 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
41 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
42 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
43 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Recruiting NCT00956007 Phase 3
44 Erlotinib Prevention of Oral Cancer (EPOC) Active, not recruiting NCT00402779 Phase 3 Erlotinib;Placebo
45 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT01141231 Phase 3
46 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
47 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
48 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer Active, not recruiting NCT00047008 Phase 3 cisplatin
49 S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat Terminated NCT00006994 Phase 3 l-glutamine placebo
50 Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer Terminated NCT00017277 Phase 3

Search NIH Clinical Center for Lip Cancer

Cochrane evidence based reviews: lip neoplasms

Genetic Tests for Lip Cancer

Anatomical Context for Lip Cancer

MalaCards organs/tissues related to Lip Cancer:

39
Lung, Breast, Liver, Brain, Lymph Node, Skin, Kidney

Publications for Lip Cancer

Articles related to Lip Cancer:

(show top 50) (show all 104)
id Title Authors Year
1
AHNS Series - Do you know your guidelines? Lip cancer. ( 28580768 )
2017
2
Clinicopathological study of lip cancer: a retrospective hospital-based study in Taiwan. ( 28913905 )
2017
3
Stage is a prognostic factor for surgically treated patients with early-stage lip cancer for whom a 'wait and see' policy in terms of neck status has been implemented. ( 28807064 )
2017
4
Intraoral stents in preventing adverse radiotherapeutic effects in lip cancer patients. ( 28883766 )
2017
5
Changes in the Incidence of Skin and Lip Cancer Between 1978 and 2007. ( 28190452 )
2017
6
Hydrochlorothiazide use is strongly associated with risk of lip cancer. ( 28480532 )
2017
7
Two-Piece Extraoral Prosthetic Rehabilitation to a Perineural Invasion Lip Cancer. ( 27517479 )
2016
8
Podoplanin, ezrin, and Rho-A proteins may have joint participation in tumor invasion of lip cancer. ( 27628318 )
2016
9
Lip cancer: A 16-year retrospective epidemiological study in Eastern part of Turkey. ( 27812062 )
2016
10
Lip Cancer: A Clinicopathological Study and Treatment Outcomes in a 25-Year Experience. ( 26917204 )
2016
11
Correlation between cell cycle proteins and hMSH2 in actinic cheilitis and lip cancer. ( 26842232 )
2016
12
High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study. ( 26830865 )
2016
13
Oral cavity and lip cancer: United Kingdom National Multidisciplinary Guidelines. ( 27841120 )
2016
14
Lip cancer and pre-cancerous lesions harbor TP53 mutations, exhibit allelic loss at 9p, 9q, and 17p, but no BRAFV600E mutations. ( 26084614 )
2015
15
Oral and lip cancer in solid organ transplant patients--a cohort study from a Swedish Transplant Centre. ( 25497104 )
2015
16
Prediction model for lymph node metastasis and recommendations for elective neck dissection in lip cancer. ( 25753473 )
2015
17
The pattern of lip cancer occurrence over the 1990-2011 period in public hospitals in Madrid, Spain. ( 26256568 )
2015
18
Facial cutaneous metastases of advanced rectal malignancy masquerading as lip cancer. ( 25370567 )
2014
19
Study of MDM2 and SUMO-1 expression in actinic cheilitis and lip cancer. ( 25241153 )
2014
20
Early diagnosis of lip cancer preceded by a persistent actinic lesion in a kidney transplant patient: a case report. ( 24983181 )
2014
21
Technique for histological control of surgical margins in lip cancer. ( 24611955 )
2014
22
Long-term outcome and subjective quality of life after surgical treatment of lower lip cancer. ( 25261402 )
2014
23
Quantification of the Surgical Margin Shrinkage in Lip Cancer: Determining the Relation Between the Surgical and Histopathologic Margins. ( 25329844 )
2014
24
Pulsed dose rate brachytherapy of lip cancer. ( 24143149 )
2013
25
Antihypertensive drugs and lip cancer in non-Hispanic whites. ( 22869299 )
2012
26
Wave technique for treatment of lower lip cancer. ( 22440315 )
2012
27
Lip cancer: a 10-year retrospective epidemiological study. ( 22493399 )
2012
28
Lip cancer: retrospective analysis of 181 cases. ( 22136191 )
2012
29
Sun protection for all: but especially for those receiving certain hypertensive medications: comment on "Antihypertensive drugs and lip cancer in non-Hispanic whites". ( 22869333 )
2012
30
High dose-rate versus low dose-rate brachytherapy for lip cancer. ( 22099044 )
2012
31
High-dose-rate interstitial brachytherapy in early stage buccal mucosa and lip cancer: report on 12 consecutive patients and review of the literature. ( 23052164 )
2012
32
Lip cancer in renal transplant patients. ( 21112239 )
2011
33
Surgical management of lip cancer. ( 21808457 )
2011
34
Occupational exposure to the sun and risk of skin and lip cancer among male wage earners in Denmark: a population-based case-control study. ( 20383781 )
2010
35
Lip cancer: a 5-year review in a tertiary referral centre. ( 20129833 )
2010
36
Lip cancer: incidence, trends, histology and survival: 1970-2006. ( 20163415 )
2010
37
Lip cancer in Western Australia, 1982-2006: a 25-year retrospective epidemiological study. ( 19473154 )
2009
38
Is elective neck dissection in T1-2, N0 patients with lower lip cancer necessary? ( 19325341 )
2009
39
Immunosuppression and other risk factors for lip cancer after kidney transplantation. ( 19190169 )
2009
40
Surgical treatment of lip cancer: our experience with 106 cases. ( 19304043 )
2009
41
Survival after lip cancer diagnosis. ( 19165039 )
2009
42
L-myc polymorphism in head and neck nonmelanoma skin and lower lip cancers. ( 18645122 )
2008
43
Comparison of time trends in lip cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents, Vols IV-VIII. ( 18573854 )
2008
44
Sentinel lymph node biopsy (SLNB) in management of N0 stage T1-T2 lip cancer as a "same day" procedure. ( 17936674 )
2008
45
Continuous intraarterial infusion chemotherapy for early lip cancer. ( 17207655 )
2007
46
Brachytherapy in lip cancer. ( 16648757 )
2006
47
5 year experience with lower lip cancer. ( 16340275 )
2005
48
Lip cancer in Zimbabwe. Report of 14 cases. ( 15695043 )
2005
49
Characterization of mast cell subpopulations in lip cancer. ( 15817069 )
2005
50
Effectiveness of brachytherapy in the treatment of lip cancer: a retrospective study at the istanbul university oncology institute. ( 16418146 )
2005

Variations for Lip Cancer

Expression for Lip Cancer

Search GEO for disease gene expression data for Lip Cancer.

Pathways for Lip Cancer

Pathways related to Lip Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 CDKN1A MDM2 MSH2 SUMO1 TP53
2
Show member pathways
13.14 BRAF CDKN1A SUMO1 TP53
3
Show member pathways
12.78 CDKN1A MDM2 MSH2 TP53
4
Show member pathways
12.54 CDKN1A MDM2 TP53
5
Show member pathways
12.5 CDKN1A MDM2 MSH2 TP53
6
Show member pathways
12.49 BRAF SUMO1 TP53
7
Show member pathways
12.48 CDKN1A MDM2 SUMO1 TP53
8
Show member pathways
12.42 CDKN1A MSH2 TP53
9
Show member pathways
12.41 MDM2 SUMO1 TP53
10
Show member pathways
12.4 CDKN1A MDM2 TP53
11 12.4 BRAF CDKN1A MDM2 MSH2 TP53
12
Show member pathways
12.36 BRAF MDM2 TP53
13 12.35 CDKN1A MDM2 TP53
14
Show member pathways
12.34 BRAF CDKN1A MDM2 MSH2 TP53
15 12.34 CDKN1A MDM2 MSH2 TP53
16
Show member pathways
12.24 CDKN1A MDM2 TP53
17
Show member pathways
12.22 CDKN1A MDM2 TP53
18 12.21 CDKN1A MDM2 TP53
19 12.15 CDKN1A MDM2 TP53
20 12.15 CDKN1A MDM2 TP53
21
Show member pathways
12.15 BRAF CDKN1A MDM2 TP53
22 12.13 BRAF CDKN1A MDM2 TP53
23
Show member pathways
12.11 CDKN1A MDM2 TP53
24 12.09 CDKN1A MDM2 TP53
25
Show member pathways
12.08 BRAF CDKN1A MDM2 TP53
26 12.01 BRAF CDKN1A MSH2 TP53
27
Show member pathways
11.97 BRAF CDKN1A MDM2
28 11.97 BRAF MDM2 MSH2 TP53
29 11.94 CDKN1A SUMO1 TP53
30 11.93 BRAF CDKN1A TP53
31 11.89 CDKN1A MDM2 SUMO1 TP53
32 11.88 CDKN1A MDM2 MSH2 TP53
33 11.86 CDKN1A MDM2 TP53
34 11.86 CDKN1A MDM2 MSH2 TP53
35 11.76 CDKN1A MDM2 SUMO1
36 11.74 CDKN1A MDM2 TP53
37
Show member pathways
11.73 CDKN1A MDM2 TP53
38 11.71 BRAF CDKN1A MDM2 TP53
39 11.69 CDKN1A MDM2 TP53
40 11.65 BRAF CDKN1A MDM2 TP53
41 11.49 MDM2 TP53
42 11.47 CDKN1A MDM2
43
Show member pathways
11.47 MDM2 SUMO1 TP53
44 11.45 MDM2 TP53
45 11.45 MDM2 TP53
46 11.42 CDKN1A TP53
47 11.42 CDKN1A TP53
48 11.42 BRAF CDKN1A MDM2 TP53
49 11.41 CDKN1A TP53
50 11.37 CDKN1A MDM2 TP53

GO Terms for Lip Cancer

Cellular components related to Lip Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.26 CDKN1A MDM2 SUMO1 TP53
2 nuclear body GO:0016604 8.92 CDKN1A MDM2 SUMO1 TP53

Biological processes related to Lip Cancer according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.76 MDM2 SUMO1 TP53
2 positive regulation of gene expression GO:0010628 9.75 BRAF MDM2 TP53
3 negative regulation of apoptotic process GO:0043066 9.71 BRAF CDKN1A MDM2 TP53
4 cell cycle arrest GO:0007050 9.63 CDKN1A MSH2 TP53
5 Ras protein signal transduction GO:0007265 9.6 CDKN1A TP53
6 cellular response to drug GO:0035690 9.59 BRAF TP53
7 cellular response to heat GO:0034605 9.57 CDKN1A SUMO1
8 response to antibiotic GO:0046677 9.56 MDM2 TP53
9 cellular response to ionizing radiation GO:0071479 9.55 CDKN1A TP53
10 positive regulation of reactive oxygen species metabolic process GO:2000379 9.54 CDKN1A TP53
11 intrinsic apoptotic signaling pathway GO:0097193 9.52 CDKN1A TP53
12 positive regulation of protein export from nucleus GO:0046827 9.51 MDM2 TP53
13 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.5 CDKN1A MDM2 TP53
14 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.49 CDKN1A TP53
15 determination of adult lifespan GO:0008340 9.48 MSH2 TP53
16 replicative senescence GO:0090399 9.43 CDKN1A TP53
17 signal transduction by p53 class mediator GO:0072331 9.37 CDKN1A TP53
18 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.33 CDKN1A MSH2 TP53
19 cellular response to actinomycin D GO:0072717 9.26 MDM2 TP53
20 cellular response to gamma radiation GO:0071480 9.13 CDKN1A MDM2 TP53
21 response to X-ray GO:0010165 8.8 CDKN1A MSH2 TP53

Molecular functions related to Lip Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.54 CDKN1A MSH2 TP53
2 p53 binding GO:0002039 9.4 MDM2 TP53
3 damaged DNA binding GO:0003684 9.32 MSH2 TP53
4 disordered domain specific binding GO:0097718 9.26 MDM2 TP53
5 enzyme binding GO:0019899 9.26 MDM2 MSH2 SUMO1 TP53
6 SUMO transferase activity GO:0019789 9.16 MDM2 SUMO1
7 ubiquitin protein ligase binding GO:0031625 8.92 CDKN1A MDM2 SUMO1 TP53

Sources for Lip Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....